Microalbuminuria, cardiovascular, and renal risk in primary hypertension

• Published in: Journal of the American Society of Nephrology Vol. 13 Suppl 3; pp. S169 - S172
• Main Authors: Pontremoli, Roberto, Leoncini, Giovanna, Ravera, Maura, Viazzi, Francesca, Vettoretti, Simone, Ratto, Elena, Parodi, Denise, Tomolillo, Cinzia, Deferrari, Giacomo
• Format: Journal Article
• Language: English
• Published: United States 01.11.2002
• Subjects: Albuminuria - etiology; Cardiovascular Diseases - etiology; Humans; Hypertension - complications; Kidney Diseases - etiology; Risk Factors
• ISSN: 1046-6673
• DOI: 10.1097/01.ASN.0000032601.86590.F7

Microalbuminuria is defined as abnormal urinary excretion of albumin between 30 and 300 mg/d. It can be measured accurately by several widely available and sensitive methods. This abnormality can be found in 8 to 15% of nondiabetic patients with primary hypertension, although its prevalence varies greatly in the literature, likely due to differences in the methods used to detect it and to the criteria applied in the selection of patients. The pathogenetic mechanisms leading to the development of microalbuminuria are still not completely known. BP load and increased systemic vascular permeability, possibly due to early endothelial damage, seem to play a major role. Increased urinary albumin excretion has been associated with several unfavorable metabolic and nonmetabolic risk factors and subclinical hypertensive organ damage. In fact, a higher prevalence of concentric left ventricular hypertrophy and subclinical impairment of left ventricular performance, as well as the presence of carotid atherosclerosis, have been reported in patients with microalbuminuria. These associations might per se justify a greater incidence of cardiovascular events. Long-term longitudinal studies have recently confirmed the unfavorable prognostic significance of microalbuminuria in hypertensive patients. It has also been hypothesized that microalbuminuria might be a forerunner of overt renal damage in primary hypertension. Clinical studies, however, have shown conflicting results, and this hypothesis has to be considered tempting but speculative at present. In conclusion, microalbuminuria is a specific, integrated marker of cardiovascular risk and target organ damage in primary hypertension and one that is suitable for identifying patients at higher global risk. A wider use of this test in the diagnostic work-up of hypertensive patients is recommended.